# The Exocrine and Endocrine Pancreas in Type 2 Diabetes, Pancreatitis and Cancer

> **NIH NIH U01** · MAYO CLINIC ROCHESTER · 2020 · $477,000

## Abstract

PROJECT SUMMARY / ABSTRACT
Since the inception of the Study of Chronic Pancreatitis, Diabetes and Pancreatic Cancer (CPDPC)
Consortium, the Mayo Clinic team has been an active participant, including leadership roles, in multiple
initiatives. A key priority of the Consortium is the facilitation of mechanism-based research of chronic
pancreatitis, pancreatogenic diabetes mellitus, and pancreatic cancer through systematically collected clinical
measures in longitudinal cohort studies linked with biospecimens. The goal of the Mayo Clinic team is to
contribute meaningfully to the most useful longitudinal cohorts that will increase our understanding of clinical,
epidemiological, and biological characterization of patients with these conditions. The primary longitudinal
cohort initiatives (outlined in the PAR) to which Mayo Clinic will continue to contribute are PROCEED and
NOD. Mayo Clinic investigators will also extend ancillary studies in PROCEED (salivary biomarkers and
internet based pain management techniques for pain in chronic pancreatitis (IMPACT)) that leverage the
extensive infrastructure in place. The Consortium has defined three Working Groups (WG) in which Mayo
Clinic investigators contribute and provide leadership (chronic pancreatitis (CP), Type 3c diabetes mellitus
(T3cDM); pancreatic cancer-DM WG. Our contribution includes solid accrual rates for these studies to date,
and successful completion of one ancillary study by the PI, active participation in the design of the NOD cohort
and subsequent modifications, and extending accrual for DETECT. Using the existing, highly productive
infrastructure we have established, our Specific Aims are to:
1) Continue to prospectively enroll and expand accrual of 100 Mayo patients into the PROCEED cohort.
 Using the clinical research infrastructure in place, we will also enroll chronic pancreatitis patients and
 subjects into ancillary studies within the CPDPC that include, among others: salivary biomarkers,
 MINIMAP, and PAIR.
2) Continue to prospectively enroll and expand accrual of 1,322 newly diagnosed diabetes patients into the
 NOD study.
3) Continue to lead and extend prospective accrual of 60 Mayo participants into the DETECT study.
To accomplish these aims, we will implement and identify new strategies to improve recruitment into the main
studies as well as ancillary studies at Mayo Clinic while providing to the CPDPC the scientific, clinical and
recruitment experience of our investigators.

## Key facts

- **NIH application ID:** 10073663
- **Project number:** 2U01DK108288-06
- **Recipient organization:** MAYO CLINIC ROCHESTER
- **Principal Investigator:** GLORIA M. PETERSEN
- **Activity code:** U01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $477,000
- **Award type:** 2
- **Project period:** 2015-09-28 → 2025-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10073663

## Citation

> US National Institutes of Health, RePORTER application 10073663, The Exocrine and Endocrine Pancreas in Type 2 Diabetes, Pancreatitis and Cancer (2U01DK108288-06). Retrieved via AI Analytics 2026-05-21 from https://api.ai-analytics.org/grant/nih/10073663. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*